Antibiotics: DALVANCE receives FDA approval
by Press Release from Outbreak News Today on (#5MMWG)
AbbVie announced Friday that the U.S. Food and Drug Administration (FDA) approved DALVANCE(R) (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth. DALVANCE is the first single-dose option administered as a 30-minute intravenous (IV) infusion for the treatment of ABSSSI caused by designated susceptible Gram-positive bacteria [...]
The post Antibiotics: DALVANCE receives FDA approval appeared first on Outbreak News Today.